19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Right Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Common Eye Conditions Tied to Higher Risk for DementiaMultigenerational Study Finds Links Between ADHD, Dementia RiskMost Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyCould Traffic Noise Raise Your Odds for Dementia?AHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?
Questions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Two Major Health Systems Won't Administer Controversial New Alzheimer's Drug

HealthDay News
by Robert Preidt and Ernie Mundell and Robin Foster
Updated: Jul 15th 2021

new article illustration

THURSDAY, July 15, 2021 (HealthDay News) -- Two major U.S. health systems say they will not administer the controversial new Alzheimer's drug Aduhelm.

The decisions by the Cleveland Clinic and Mount Sinai's Health System in New York City are the latest fallout from the U.S. Food and Drug Administration's widely criticized approval of the Biogen drug on June 7, The New York Times reported.

Many experts say there's no clear evidence the drug helps slow mental decline in Alzheimer's patients, and the approval has triggered congressional investigations.

After an expert panel review of "all available scientific evidence on this medication," the Cleveland Clinic has decided not to carry the drug at this time, the clinic said in a statement, the Times reported.

Individual doctors can prescribe Aduhelm, but those patients would have to go elsewhere to receive the drug that's administered as a monthly intravenous infusion, the clinic added.

Mount Sinai's decision not to administer Aduhelm was influenced by calls for a federal investigation into the FDA decision and the agency's relationship with Biogen, Dr. Sam Gandy, director of the Mount Sinai Center for Cognitive Health in New York City, told the Times.

Many Alzheimer's experts have said that it is unclear that the drug actually slows cognitive decline while there is also evidence that Aduhelm could cause brain swelling or bleeding, the Times reported. The drug is also expensive, with a price tag pegged at $56,000 a year.

In a recent survey of nearly 200 neurologists and primary care doctors, most said they disagreed with the FDA decision and did not plan to prescribe the drug to their patients, the Times reported.

Last week, in response to growing criticism, acting FDA Commissioner Dr. Janet Woodcock called for an independent federal investigation into the agency's approval process.

"To the extent these concerns could undermine the public's confidence in FDA's decision, I believe it is critical that the events at issue be reviewed by an independent body," she said at the time.

More information

Visit the National Institute on Aging for more on Alzheimer's disease.


SOURCE: The New York Times